eALM1137

eALM1137 (0.1-1000 nM; 5 days) potently inhibits U87-MG glioblastoma cell proliferation with an EC₅₀ of 5.1 nM after 5 days of treatment^[1].
eALM1137 (0.1-1000 nM; 5 days) potently inhibits T98G glioblastoma cell proliferation with an EC₅₀ of 11 nM after 5 days of treatment^[1].
eALM1137 (3 nM, 10 nM, 30 nM, 100 nM, 300 nM) dose-dependently inhibits mTORC1 and mTORC2 signaling in U87-MG and T98G glioblastoma cells, with marked reduction of phosphorylated S6 and Akt at concentrations ≥30 nM^[1].
eALM1137 (10^-8-10^-5 M; 3 days) potently inhibits NPE glioblastoma stem cell proliferation with an EC₅₀ of 85 nM after 3 days of treatment, exerting cytostatic rather than cytotoxic effects^[1].
eALM1137 (300 nM; 24 h) inhibits mTORC1 and mTORC2 signaling in NPE glioblastoma stem cells after 24 h of treatment at 300 nM, while inducing compensatory activation of the RAF-MEK-ERK pathway^[1].
eALM1137 (0.03 μM, 0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM; 3 days) induces dose-dependent G1-phase cell cycle arrest in E21 patient-derived glioblastoma stem cells after 3 days of treatment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.